Tags

Type your tag names separated by a space and hit enter

Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
Monaldi Arch Chest Dis 1993; 48(3):205-9MA

Abstract

A study was carried out in six human volunteers, to assess the blood kinetics of isoniazid, rifampicin and pyrazinamide, administered in a fixed-triple combination intended for use in intermittent chemotherapy of tuberculosis. The formulation employed contained 125 mg of isoniazid (H), 100 mg of rifampicin (R) and 375 mg of pyrazinamide (Z) per tablet; six tablets were administered to every subject, giving a total dosage of 750 mg of isoniazid, 600 mg of rifampicin and 2,250 mg of pyrazinamide. In each subject, the same dose of each drug was administered individually in separate sessions and the results compared. The results indicated that, at the level of dose of the intermittent tablet, no negative interactions between the drugs were observed.

Authors+Show Affiliations

Reference Center for Chemotherapy of Mycobacterial Diseases, IRCCS San Matteo Hospital, Pavia, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

8369784

Citation

Acocella, G, et al. "Bioavailability of Isoniazid, Rifampicin and Pyrazinamide (in Free Combination or Fixed-triple Formulation) in Intermittent Antituberculous Chemotherapy." Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace, vol. 48, no. 3, 1993, pp. 205-9.
Acocella G, Luisetti M, Grassi GG, et al. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy. Monaldi Arch Chest Dis. 1993;48(3):205-9.
Acocella, G., Luisetti, M., Grassi, G. G., Peona, V., Pozzi, E., & Grassi, C. (1993). Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy. Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace, 48(3), pp. 205-9.
Acocella G, et al. Bioavailability of Isoniazid, Rifampicin and Pyrazinamide (in Free Combination or Fixed-triple Formulation) in Intermittent Antituberculous Chemotherapy. Monaldi Arch Chest Dis. 1993;48(3):205-9. PubMed PMID: 8369784.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy. AU - Acocella,G, AU - Luisetti,M, AU - Grassi,G G, AU - Peona,V, AU - Pozzi,E, AU - Grassi,C, PY - 1993/1/1/pubmed PY - 1993/1/1/medline PY - 1993/1/1/entrez SP - 205 EP - 9 JF - Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace JO - Monaldi Arch Chest Dis VL - 48 IS - 3 N2 - A study was carried out in six human volunteers, to assess the blood kinetics of isoniazid, rifampicin and pyrazinamide, administered in a fixed-triple combination intended for use in intermittent chemotherapy of tuberculosis. The formulation employed contained 125 mg of isoniazid (H), 100 mg of rifampicin (R) and 375 mg of pyrazinamide (Z) per tablet; six tablets were administered to every subject, giving a total dosage of 750 mg of isoniazid, 600 mg of rifampicin and 2,250 mg of pyrazinamide. In each subject, the same dose of each drug was administered individually in separate sessions and the results compared. The results indicated that, at the level of dose of the intermittent tablet, no negative interactions between the drugs were observed. SN - 1122-0643 UR - https://www.unboundmedicine.com/medline/citation/8369784/Bioavailability_of_isoniazid_rifampicin_and_pyrazinamide__in_free_combination_or_fixed_triple_formulation__in_intermittent_antituberculous_chemotherapy_ DB - PRIME DP - Unbound Medicine ER -